Table 1 Biological pathways enriched by up-regulated genes in OA-affected tissue from the GSE179716 and the GSE206848 data sets. Analysis performed using platform FunRich. * p < 0.05; ** p < 0.005; *** p < 0.001.
Biological pathway enriched by up-regulated genes | Percentage of genes involved in enriched pathway | ||
|---|---|---|---|
OA-affected chondrocytes | OA-affected synoviocytes | p | |
Adherens junctions interactions | 0.29% | 0.83% | * |
Alpha9 beta1 integrin signaling events | 27.18% | 25.21% | * |
Arf6 downstream pathway | 26.60% | 25.21% | * |
Arf6 signaling events | 26.60% | 25.21% | * |
Arf6 trafficking events | 26.60% | 25.21% | * |
Aurora A signaling | 2.03% | 0.62% | * |
Aurora B signaling | 2.03% | 0.62% | * |
Axon guidance | 6.69% | 4.75% | * |
Beta1 integrin cell surface interactions | 30.38% | 25.41% | *** |
Beta3 integrin cell surface interactions | 2.33% | 0.41% | ** |
Cell cycle. mitotic | 9.16% | 4.96% | ** |
Cell-extracellular matrix interactions | 1.16% | 0.21% | * |
Class I PI3K signaling events | 26.60% | 25.21% | * |
Class I PI3K signaling events mediated by Akt | 26.60% | 25.21% | * |
C-MYC pathway | 4.22% | 2.69% | * |
Cyclin D associated events in G1 | 1.16% | 0.41% | * |
DNA replication | 7.12% | 4.34% | * |
EGF receptor (ErbB1) signaling pathway | 26.60% | 25.21% | * |
EGFR1 | 2.76% | 3.31% | * |
EGFR-dependent endothelin signaling events | 26.74% | 25.21% | * |
Endothelins | 27.47% | 25.62% | ** |
Epithelial-to-mesenchymal transition | 5.96% | 1.03% | ** |
ErbB receptor signaling network | 26.89% | 25.41% | * |
ErbB1 downstream signaling | 26.60% | 25.21% | * |
FOXM1 transcription factor network | 2.18% | 0.62% | * |
Gene expression | 0.87% | 3.72% | * |
Glucocorticoid receptor regulatory network | 1.16% | 2.07% | * |
Glypican 1 network | 26.89% | 25.21% | * |
Glypican pathway | 28.05% | 25.83% | ** |
GMCSF-mediated signaling events | 26.60% | 25.21% | * |
Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis | 0.29% | 1.45% | * |
IFN-gamma pathway | 26.6% | 25.21% | * |
IGF1 pathway | 26.74% | 25.21% | * |
IL1-mediated signaling events | 5.38% | 4.34% | * |
IL3-mediated signaling events | 26.6% | 25.21% | * |
IL5-mediated signaling events | 26.60% | 25.21% | * |
Insulin pathway | 26.60% | 25.21% | * |
Integrin cell surface interactions | 3.63% | 1.45% | *** |
Integrin family cell surface interactions | 30.81% | 25.41% | *** |
Internalization of ErbB1 | 26.60% | 25.21% | * |
LKB1 signaling events | 27.33% | 25.41% | * |
Metabolism of RNA | 1.74% | 3.31% | * |
Mitotic M-M/G1 phases | 6.54% | 4.34% | * |
mTOR signaling pathway | 26.60% | 25.21% | * |
Muscle contraction | 2.76% | 1.65% | *** |
Olfactory signaling pathway | 0.15% | 1.86% | * |
PAR1-mediated thrombin signaling events | 27.18% | 25.21% | * |
PD-1 signaling | 0.00% | 0.41% | * |
PDGF receptor signaling network | 26.74% | 25.21% | * |
PDGFR-beta signaling pathway | 26.60% | 25.21% | * |
Plasma membrane estrogen receptor signaling | 27.33% | 25.21% | ** |
Proteoglycan syndecan-mediated signaling events | 28.49% | 25.83% | ** |
Response to elevated platelet cytosolic Ca2+ | 2.33% | 0.83% | ** |
S1P1 pathway | 26.60% | 25.21% | * |
Signaling events mediated by focal adhesion kinase | 26.60% | 25.21% | * |
Signaling events mediated by hepatocyte growth factor receptor (c-Met) | 26.60% | 25.21% | * |
Signaling events mediated by VEGFR1 and VEGFR2 | 26.74% | 25.21% | * |
Smooth muscle contraction | 2.47% | 0.83% | *** |
Syndecan-1-mediated signaling events | 26.89% | 25.21% | * |
Syndecan-2-mediated signaling events | 3.49% | 1.86% | ** |
Thrombin/protease-activated receptor (PAR) pathway | 27.18% | 25.21% | * |
TRAIL signaling pathway | 27.18% | 26.03% | * |
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | 26.60% | 25.21% | * |
VEGF and VEGFR signaling network | 27.03% | 25.21% | * |